ASTRAL-2 and ASTRAL-3, are designed to determine whether guadecitabine (SGI-110), a potent second-generation hypomethylating agent, could answer the unmet medical needs for AML, MDS, and CMML.
More From BioPortfolio on "Potent Hypomethylating Agent Is Tested in 2 Hematologic Malignancy Trials"